CD20 Antibodies & Proteins: Research Tools for B Cell Lymphoma and Autoimmune Disease

CD20 (MS4A1) is a B cell surface antigen expressed from pre-B cell through mature B cell stages but absent on plasma cells and stem cells, making it an ideal target for B cell-directed therapies. For a broader oncology reagent overview, see our Cancer Research Reagents hub.

Target Biology and Clinical Relevance

Rituximab (anti-CD20) was the first monoclonal antibody approved for cancer treatment (1997) and remains a cornerstone of lymphoma therapy. Second- and third-generation anti-CD20 antibodies (obinutuzumab, ofatumumab) have been developed with enhanced Fc-mediated effector functions.

CD20 is targeted through multiple mechanisms: direct signaling (apoptosis), ADCC (NK cell-mediated killing), CDC (complement-dependent cytotoxicity), and ADCP (antibody-dependent cellular phagocytosis). Research reagents for each mechanism include detection antibodies, blocking antibodies, and functional assay systems. The CD47/SIRPα axis ("don't eat me" signal) is increasingly studied alongside CD20-targeting strategies to enhance macrophage-mediated phagocytosis of B cell lymphomas.

Research biosimilar rituximab is one of the most commonly used research-grade therapeutic antibodies, serving as a reference standard in biosimilar development programs, PK/ADA assays, and ADCC/CDC potency assays. For a detailed comparison of how research biosimilars differ from originator drugs, see our Biosimilar vs. Originator guide.

Anti-CD20 antibodies for flow cytometry must be validated on unfixed cells (CD20 is partially destroyed by some fixatives). Clones that work on paraformaldehyde-fixed cells should be specifically confirmed. For guidance on antibody validation in different fixation conditions, see our Antibody Specificity and Validation guide.

abinScience Product Coverage

References

1. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195. doi: 10.1182/blood.V90.6.2188

2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

All products are for research use only. For technical support, contact order@abinscience.com.